The Food and Drug Administration has ordered a new warning on every GLP-1 drug sold in the United States, including Ozempic, Wegovy, Mounjaro and Zepbound. The warning is about a rare eye condition that can cause sudden vision loss, and in some cases permanent vision loss.
The FDA announced the change on Monday, Nov. 9. It is a labeling change, not a recall, and the drugs are still on the market. But for millions of people who take these drugs for diabetes or weight loss, the label is about to look different, and they deserve to know why.
What is the warning about?
The condition is called non-arteritic anterior ischemic optic neuropathy, or NAION. It happens when blood flow drops to part of the optic nerve, which carries signals from the eye to the brain.
The FDA describes NAION as a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss. Symptoms listed by the FDA include sudden, painless vision loss in one eye that people may notice when they wake up, along with blind spots, tunnel vision, distorted colors and hazy or blurry patches.
Which drugs are covered?
The order covers all approved GLP-1 receptor agonists, about a dozen drugs. The FDA said NAION cases have been reported for every GLP-1 product currently on the U.S. market.
The list includes Ozempic, Wegovy and Rybelsus, which use semaglutide and are made by Novo Nordisk, Mounjaro and Zepbound, which use tirzepatide and are made by Eli Lilly, Victoza and Saxenda, which use liraglutide, Trulicity, which uses dulaglutide, and the combination products Xultophy and Soliqua, and Foundayo, which was approved in 2026.
What did the FDA actually find?
The agency pooled 126 randomized controlled trials with a total of 134,253 patients. It found 15 probable NAION cases: 10 among patients taking GLP-1 drugs and five among patients on a placebo or a non-GLP-1 diabetes drug. The FDA said the review showed a NAION rate of 6.4 per 100,000 patients treated with a GLP-1, compared to 3.8 per 100,000 in comparison groups.
In plain terms, the risk is rare, and it was higher in the GLP-1 group in the trials the FDA reviewed. The agency said it did not determine whether GLP-1 drugs cause NAION, only that the evidence suggests they may increase the risk. That distinction matters, and it is why the warning uses the words potential increased risk.
What the drugmakers say
Novo Nordisk, which makes Ozempic and Wegovy, told Reuters it continues to believe the data do not establish a cause-and-effect relationship, and it remains confident in the drugs’ benefit-risk profile. Eli Lilly noted the warning applies to all GLP-1 drugs, not just its products.
Here is the bottom line. These drugs help a lot of people, and the FDA is not pulling them. But a warning this broad, covering every drug in the class, is not routine. It is the FDA saying the risk is real enough to put on the label, even if it is rare and even if causation is not proven. Patients deserve to see that warning before they take the next dose, not after.
Sources
- USA Today: FDA says popular GLP-1 drugs linked to rare risk of vision loss, blindness
- Drugs.com: Rare Eye Condition Prompts New FDA Warning On Popular GLP-1 Drugs
- Men’s Journal: Ozempic, Zepbound Vision Loss Warning: What the FDA Found
Leave a Comment